589 related articles for article (PubMed ID: 16728496)
1. Peroxisome proliferator-activated receptor (PPAR)-alpha agonism prevents the onset of type 2 diabetes in Zucker diabetic fatty rats: A comparison with PPAR gamma agonism.
Bergeron R; Yao J; Woods JW; Zycband EI; Liu C; Li Z; Adams A; Berger JP; Zhang BB; Moller DE; Doebber TW
Endocrinology; 2006 Sep; 147(9):4252-62. PubMed ID: 16728496
[TBL] [Abstract][Full Text] [Related]
2. Ameliorating effect of FK614, a novel nonthiazolidinedione peroxisome proliferator-activated receptor gamma agonist, on insulin resistance in Zucker fatty rat.
Minoura H; Takeshita S; Yamamoto T; Mabuchi M; Hirosumi J; Takakura S; Kawamura I; Seki J; Manda T; Ita M; Mutoh S
Eur J Pharmacol; 2005 Sep; 519(1-2):182-90. PubMed ID: 16039648
[TBL] [Abstract][Full Text] [Related]
3. Effects of cevoglitazar, a dual PPARalpha/gamma agonist, on ectopic fat deposition in fatty Zucker rats.
Laurent D; Gounarides JS; Gao J; Boettcher BR
Diabetes Obes Metab; 2009 Jun; 11(6):632-6. PubMed ID: 19175377
[TBL] [Abstract][Full Text] [Related]
4. A tailored therapy for the metabolic syndrome: the dual peroxisome proliferator-activated receptor-alpha/gamma agonist LY465608 ameliorates insulin resistance and diabetic hyperglycemia while improving cardiovascular risk factors in preclinical models.
Etgen GJ; Oldham BA; Johnson WT; Broderick CL; Montrose CR; Brozinick JT; Misener EA; Bean JS; Bensch WR; Brooks DA; Shuker AJ; Rito CJ; McCarthy JR; Ardecky RJ; Tyhonas JS; Dana SL; Bilakovics JM; Paterniti JR; Ogilvie KM; Liu S; Kauffman RF
Diabetes; 2002 Apr; 51(4):1083-7. PubMed ID: 11916929
[TBL] [Abstract][Full Text] [Related]
5. Attenuation of type 2 diabetes mellitus in the male Zucker diabetic fatty rat: the effects of stress and non-volitional exercise.
Király MA; Bates HE; Yue JT; Goche-Montes D; Fediuc S; Park E; Matthews SG; Vranic M; Riddell MC
Metabolism; 2007 Jun; 56(6):732-44. PubMed ID: 17512304
[TBL] [Abstract][Full Text] [Related]
6. A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia.
Reifel-Miller A; Otto K; Hawkins E; Barr R; Bensch WR; Bull C; Dana S; Klausing K; Martin JA; Rafaeloff-Phail R; Rafizadeh-Montrose C; Rhodes G; Robey R; Rojo I; Rungta D; Snyder D; Wilbur K; Zhang T; Zink R; Warshawsky A; Brozinick JT
Mol Endocrinol; 2005 Jun; 19(6):1593-605. PubMed ID: 15831517
[TBL] [Abstract][Full Text] [Related]
7. Peroxisome proliferator-activated receptor (PPAR)-alpha activation prevents diabetes in OLETF rats: comparison with PPAR-gamma activation.
Koh EH; Kim MS; Park JY; Kim HS; Youn JY; Park HS; Youn JH; Lee KU
Diabetes; 2003 Sep; 52(9):2331-7. PubMed ID: 12941773
[TBL] [Abstract][Full Text] [Related]
8. Cevoglitazar, a novel peroxisome proliferator-activated receptor-alpha/gamma dual agonist, potently reduces food intake and body weight in obese mice and cynomolgus monkeys.
Chen H; Dardik B; Qiu L; Ren X; Caplan SL; Burkey B; Boettcher BR; Gromada J
Endocrinology; 2010 Jul; 151(7):3115-24. PubMed ID: 20484464
[TBL] [Abstract][Full Text] [Related]
9. Recurrent intermittent restraint delays fed and fasting hyperglycemia and improves glucose return to baseline levels during glucose tolerance tests in the Zucker diabetic fatty rat--role of food intake and corticosterone.
Bates HE; Kiraly MA; Yue JT; Goche Montes D; Elliott ME; Riddell MC; Matthews SG; Vranic M
Metabolism; 2007 Aug; 56(8):1065-75. PubMed ID: 17618951
[TBL] [Abstract][Full Text] [Related]
10. Improvement of glucose tolerance in Zucker diabetic fatty rats by long-term treatment with the dipeptidyl peptidase inhibitor P32/98: comparison with and combination with rosiglitazone.
Wargent E; Stocker C; Augstein P; Heinke P; Meyer A; Hoffmann T; Subramanian A; Sennitt MV; Demuth HU; Arch JR; Cawthorne MA
Diabetes Obes Metab; 2005 Mar; 7(2):170-81. PubMed ID: 15715890
[TBL] [Abstract][Full Text] [Related]
11. Energy restriction prevents the development of type 2 diabetes in Zucker diabetic fatty rats: coordinated patterns of gene expression for energy metabolism in insulin-sensitive tissues and pancreatic islets determined by oligonucleotide microarray analysis.
Colombo M; Kruhoeffer M; Gregersen S; Agger A; Jeppesen P; Oerntoft T; Hermansen K
Metabolism; 2006 Jan; 55(1):43-52. PubMed ID: 16324918
[TBL] [Abstract][Full Text] [Related]
12. The dual PPARalpha/gamma agonist, ragaglitazar, improves insulin sensitivity and metabolic profile equally with pioglitazone in diabetic and dietary obese ZDF rats.
Pickavance LC; Brand CL; Wassermann K; Wilding JP
Br J Pharmacol; 2005 Feb; 144(3):308-16. PubMed ID: 15655531
[TBL] [Abstract][Full Text] [Related]
13. Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus.
Bajaj M; Suraamornkul S; Hardies LJ; Glass L; Musi N; DeFronzo RA
Diabetologia; 2007 Aug; 50(8):1723-31. PubMed ID: 17520238
[TBL] [Abstract][Full Text] [Related]
14. Effects of the dual PPAR-α/γ agonist aleglitazar on glycaemic control and organ protection in the Zucker diabetic fatty rat.
Bénardeau A; Verry P; Atzpodien EA; Funk JM; Meyer M; Mizrahi J; Winter M; Wright MB; Uhles S; Sebokova E
Diabetes Obes Metab; 2013 Feb; 15(2):164-74. PubMed ID: 22958363
[TBL] [Abstract][Full Text] [Related]
15. Antidiabetic effect of a novel non-thiazolidinedione PPAR gamma/alpha agonist on ob/ob mice.
Hu X; Feng Y; Shen Y; Zhao XF; Yu JH; Yang YS; Leng Y
Acta Pharmacol Sin; 2006 Oct; 27(10):1346-52. PubMed ID: 17007742
[TBL] [Abstract][Full Text] [Related]
16. Effect of PPAR-alpha and -gamma agonist on the expression of visfatin, adiponectin, and TNF-alpha in visceral fat of OLETF rats.
Choi KC; Ryu OH; Lee KW; Kim HY; Seo JA; Kim SG; Kim NH; Choi DS; Baik SH; Choi KM
Biochem Biophys Res Commun; 2005 Oct; 336(3):747-53. PubMed ID: 16157299
[TBL] [Abstract][Full Text] [Related]
17. Effects of combined PPAR-γ and PPAR-α agonist therapy on fructose induced NASH in rats: Modulation of gene expression.
Abd El-Haleim EA; Bahgat AK; Saleh S
Eur J Pharmacol; 2016 Feb; 773():59-70. PubMed ID: 26825546
[TBL] [Abstract][Full Text] [Related]
18. A novel N-aryl tyrosine activator of peroxisome proliferator-activated receptor-gamma reverses the diabetic phenotype of the Zucker diabetic fatty rat.
Brown KK; Henke BR; Blanchard SG; Cobb JE; Mook R; Kaldor I; Kliewer SA; Lehmann JM; Lenhard JM; Harrington WW; Novak PJ; Faison W; Binz JG; Hashim MA; Oliver WO; Brown HR; Parks DJ; Plunket KD; Tong WQ; Menius JA; Adkison K; Noble SA; Willson TM
Diabetes; 1999 Jul; 48(7):1415-24. PubMed ID: 10389847
[TBL] [Abstract][Full Text] [Related]
19. Diazoxide attenuates insulin secretion and hepatic lipogenesis in zucker diabetic fatty rats.
Alemzadeh R; Tushaus K
Med Sci Monit; 2005 Dec; 11(12):BR439-48. PubMed ID: 16319780
[TBL] [Abstract][Full Text] [Related]
20. Neurturin and a GLP-1 Analogue Act Synergistically to Alleviate Diabetes in Zucker Diabetic Fatty Rats.
Trevaskis JL; Sacramento CB; Jouihan H; Ali S; Le Lay J; Oldham S; Bhagroo N; Boland BB; Cann J; Chang Y; O'Day T; Howard V; Reers C; Winzell MS; Smith DM; Feigh M; Barkholt P; Schreiter K; Austen M; Andag U; Thompson S; Jermutus L; Coghlan MP; Grimsby J; Dohrmann C; Rhodes CJ; Rondinone CM; Sharma A
Diabetes; 2017 Jul; 66(7):2007-2018. PubMed ID: 28408435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
